Review



anti zw10  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech anti zw10
    Anti Zw10, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zw10/ZW10+Antibody/pm40831774-57-24-29
    Average 93 stars, based on 15 article reviews
    anti zw10 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    Western Blot:

    Article Title: Rab18 promotes lipid droplet (LD) growth by tethering the ER to LDs through SNARE and NRZ interactions
    Article Snippet: Antibodies against Rab3GAP1 (rabbit, HPA034495); Rab3GAP2 (rabbit, HPA026273), NAG (rabbit, HPA036817; used for IF), Use1 (rabbit, HPA047562), and Ykt6 (rabbit, HPA030817) were obtained from Human Protein Atlas. .. Antibodies against Rab18 (mouse, 60057–1-Ig; used for IF) and ZW10 (rabbit, 24561–1-AP; used for Western blot) were obtained from Proteintech. .. Antibody against ACSL3 (mouse, H00002181-B0) was obtained from Abnova.

    Article Title: Rab18 promotes lipid droplet (LD) growth by tethering the ER to LDs through SNARE and NRZ interactions.
    Article Snippet: Antibodies against Rab3GAP1 (rabbit, HPA034495); Rab3GAP2 (rabbit, HPA026273), NAG (rabbit, HPA036817; used for IF), Use1 (rabbit, HPA047562), and Ykt6 (rabbit, HPA030817) were obtained from Human Protein Atlas. .. Antibodies against Rab18 (mouse, 60057–1-Ig; used for IF) and ZW10 (rabbit, 24561–1-AP; used for Western blot) were obtained from Proteintech. .. Antibody against ACSL3 (mouse, H00002181-B0) was obtained from Abnova.

    Article Title: PAUF/ZG16B promotes colorectal cancer progression through alterations of the mitotic functions and the Wnt/β-catenin pathway.
    Article Snippet: FLP-IN 293 T-REX cells (Life Technologies) were cultured with 100 μg/ml of Zeozin (Invitrogen) and 15 μg/ml of blasticidin (Invitrogen). .. Antibodies used were lamin B (C-20), RhoGDI (Rho GDP-dissociation inhibitor; A-20), DVL1 (3F12), NAP1L1 (sc-81328), Zw10 (sc-81430) and α-tubulin (B-7) (from Santa Cruz Biotechnology), E-cadherin (Clone 36; BD Biosciences), β-catenin (9562; Cell Signaling Technology), PUM1 (26256-1-AP, Proteintech), APC (MAB3785 for immunofluorescence and MABC202 for immunoblotting, Millipore) and MTA2 (ab8106; Abcam). ..

    Immunofluorescence:

    Article Title: PAUF/ZG16B promotes colorectal cancer progression through alterations of the mitotic functions and the Wnt/β-catenin pathway.
    Article Snippet: FLP-IN 293 T-REX cells (Life Technologies) were cultured with 100 μg/ml of Zeozin (Invitrogen) and 15 μg/ml of blasticidin (Invitrogen). .. Antibodies used were lamin B (C-20), RhoGDI (Rho GDP-dissociation inhibitor; A-20), DVL1 (3F12), NAP1L1 (sc-81328), Zw10 (sc-81430) and α-tubulin (B-7) (from Santa Cruz Biotechnology), E-cadherin (Clone 36; BD Biosciences), β-catenin (9562; Cell Signaling Technology), PUM1 (26256-1-AP, Proteintech), APC (MAB3785 for immunofluorescence and MABC202 for immunoblotting, Millipore) and MTA2 (ab8106; Abcam). ..



    Similar Products

    anti zw10  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology anti zw10
    K250-BubR1 acetylation is involved in the maintenance of crescent-shaped fibrous corona. ( A ) Representative images of immunostaining with anti-MAD2 <t>and</t> <t>anti-ZW10</t> antibodies after induction of BubR1-WT, -K250R , and -K250Q expression in HeLa-FRT-TO cells. Nocodazole (200 ng/ml) alone or with MG132 was applied before fixation. Endogenous BubR1 was depleted via siRNA. Scale bar, 5 μm. ( B ) Representative SIM images of immunostained ZW10 at kinetochores of HeLa cells expressing FLAG-tagged BubR1-WT, -K250R , or -K250Q following double thymidine block and release. FRT/TO HeLa cells were treated with doxycycline for 55 h to induce expression of ectopic BubR1 variants. Endogenous BubR1 was depleted using siRNA targeting the 3′ UTR. Cells were fixed for immunostaining 10 h after the final thymidine release to enrich the mitotic population. ( C ) Effects of BubR1 acetylation status on CENP-E and RZZ complex formation. Cells were treated with nocodazole alone (+Noc) or with MG132 (+Noc + MG132). Relative protein levels were measured using a densitometer, and the ratios are indicated at the bottom. ( D ) Representative images showing immunostained ZW10 and anti-CENP-A antibodies in FRT/TO HeLa cells expressing BubR1-WT, K250R , or K250Q with (siCtrl) or without CENP-E (siCENP-E). Cells were transfected with siRNA targeting luciferase (siCtrl) or CENP-E (siCENP-E) for 48 h prior to fixation. Nocodazole was administered for 20 h before analysis.
    Anti Zw10, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zw10/ZW10+Antibody/pmc12802887-48-58-60
    Average 93 stars, based on 1 article reviews
    anti zw10 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti zw10  (Proteintech)
    93
    Proteintech anti zw10
    K250-BubR1 acetylation is involved in the maintenance of crescent-shaped fibrous corona. ( A ) Representative images of immunostaining with anti-MAD2 <t>and</t> <t>anti-ZW10</t> antibodies after induction of BubR1-WT, -K250R , and -K250Q expression in HeLa-FRT-TO cells. Nocodazole (200 ng/ml) alone or with MG132 was applied before fixation. Endogenous BubR1 was depleted via siRNA. Scale bar, 5 μm. ( B ) Representative SIM images of immunostained ZW10 at kinetochores of HeLa cells expressing FLAG-tagged BubR1-WT, -K250R , or -K250Q following double thymidine block and release. FRT/TO HeLa cells were treated with doxycycline for 55 h to induce expression of ectopic BubR1 variants. Endogenous BubR1 was depleted using siRNA targeting the 3′ UTR. Cells were fixed for immunostaining 10 h after the final thymidine release to enrich the mitotic population. ( C ) Effects of BubR1 acetylation status on CENP-E and RZZ complex formation. Cells were treated with nocodazole alone (+Noc) or with MG132 (+Noc + MG132). Relative protein levels were measured using a densitometer, and the ratios are indicated at the bottom. ( D ) Representative images showing immunostained ZW10 and anti-CENP-A antibodies in FRT/TO HeLa cells expressing BubR1-WT, K250R , or K250Q with (siCtrl) or without CENP-E (siCENP-E). Cells were transfected with siRNA targeting luciferase (siCtrl) or CENP-E (siCENP-E) for 48 h prior to fixation. Nocodazole was administered for 20 h before analysis.
    Anti Zw10, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zw10/ZW10+Antibody/pm40831774-57-24-29
    Average 93 stars, based on 1 article reviews
    anti zw10 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    zw10 polyclonal antibody  (Proteintech)
    93
    Proteintech zw10 polyclonal antibody
    K250-BubR1 acetylation is involved in the maintenance of crescent-shaped fibrous corona. ( A ) Representative images of immunostaining with anti-MAD2 <t>and</t> <t>anti-ZW10</t> antibodies after induction of BubR1-WT, -K250R , and -K250Q expression in HeLa-FRT-TO cells. Nocodazole (200 ng/ml) alone or with MG132 was applied before fixation. Endogenous BubR1 was depleted via siRNA. Scale bar, 5 μm. ( B ) Representative SIM images of immunostained ZW10 at kinetochores of HeLa cells expressing FLAG-tagged BubR1-WT, -K250R , or -K250Q following double thymidine block and release. FRT/TO HeLa cells were treated with doxycycline for 55 h to induce expression of ectopic BubR1 variants. Endogenous BubR1 was depleted using siRNA targeting the 3′ UTR. Cells were fixed for immunostaining 10 h after the final thymidine release to enrich the mitotic population. ( C ) Effects of BubR1 acetylation status on CENP-E and RZZ complex formation. Cells were treated with nocodazole alone (+Noc) or with MG132 (+Noc + MG132). Relative protein levels were measured using a densitometer, and the ratios are indicated at the bottom. ( D ) Representative images showing immunostained ZW10 and anti-CENP-A antibodies in FRT/TO HeLa cells expressing BubR1-WT, K250R , or K250Q with (siCtrl) or without CENP-E (siCENP-E). Cells were transfected with siRNA targeting luciferase (siCtrl) or CENP-E (siCENP-E) for 48 h prior to fixation. Nocodazole was administered for 20 h before analysis.
    Zw10 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zw10/ZW10+Antibody/pm40940405-102-19-24
    Average 93 stars, based on 1 article reviews
    zw10 polyclonal antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    fusion between the c-terminal domain of spc105r and the entire coding region of zw10  (GenScript corporation)
    90
    GenScript corporation fusion between the c-terminal domain of spc105r and the entire coding region of zw10
    K250-BubR1 acetylation is involved in the maintenance of crescent-shaped fibrous corona. ( A ) Representative images of immunostaining with anti-MAD2 <t>and</t> <t>anti-ZW10</t> antibodies after induction of BubR1-WT, -K250R , and -K250Q expression in HeLa-FRT-TO cells. Nocodazole (200 ng/ml) alone or with MG132 was applied before fixation. Endogenous BubR1 was depleted via siRNA. Scale bar, 5 μm. ( B ) Representative SIM images of immunostained ZW10 at kinetochores of HeLa cells expressing FLAG-tagged BubR1-WT, -K250R , or -K250Q following double thymidine block and release. FRT/TO HeLa cells were treated with doxycycline for 55 h to induce expression of ectopic BubR1 variants. Endogenous BubR1 was depleted using siRNA targeting the 3′ UTR. Cells were fixed for immunostaining 10 h after the final thymidine release to enrich the mitotic population. ( C ) Effects of BubR1 acetylation status on CENP-E and RZZ complex formation. Cells were treated with nocodazole alone (+Noc) or with MG132 (+Noc + MG132). Relative protein levels were measured using a densitometer, and the ratios are indicated at the bottom. ( D ) Representative images showing immunostained ZW10 and anti-CENP-A antibodies in FRT/TO HeLa cells expressing BubR1-WT, K250R , or K250Q with (siCtrl) or without CENP-E (siCENP-E). Cells were transfected with siRNA targeting luciferase (siCtrl) or CENP-E (siCENP-E) for 48 h prior to fixation. Nocodazole was administered for 20 h before analysis.
    Fusion Between The C Terminal Domain Of Spc105r And The Entire Coding Region Of Zw10, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zw10/a+fusion+between+the+c+terminal+domain+of+spc105r+and+the+entire+coding+region+of+z+w10/pm39879252-348-14-18
    Average 90 stars, based on 1 article reviews
    fusion between the c-terminal domain of spc105r and the entire coding region of zw10 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mouse anti zw10  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology mouse anti zw10
    K250-BubR1 acetylation is involved in the maintenance of crescent-shaped fibrous corona. ( A ) Representative images of immunostaining with anti-MAD2 <t>and</t> <t>anti-ZW10</t> antibodies after induction of BubR1-WT, -K250R , and -K250Q expression in HeLa-FRT-TO cells. Nocodazole (200 ng/ml) alone or with MG132 was applied before fixation. Endogenous BubR1 was depleted via siRNA. Scale bar, 5 μm. ( B ) Representative SIM images of immunostained ZW10 at kinetochores of HeLa cells expressing FLAG-tagged BubR1-WT, -K250R , or -K250Q following double thymidine block and release. FRT/TO HeLa cells were treated with doxycycline for 55 h to induce expression of ectopic BubR1 variants. Endogenous BubR1 was depleted using siRNA targeting the 3′ UTR. Cells were fixed for immunostaining 10 h after the final thymidine release to enrich the mitotic population. ( C ) Effects of BubR1 acetylation status on CENP-E and RZZ complex formation. Cells were treated with nocodazole alone (+Noc) or with MG132 (+Noc + MG132). Relative protein levels were measured using a densitometer, and the ratios are indicated at the bottom. ( D ) Representative images showing immunostained ZW10 and anti-CENP-A antibodies in FRT/TO HeLa cells expressing BubR1-WT, K250R , or K250Q with (siCtrl) or without CENP-E (siCENP-E). Cells were transfected with siRNA targeting luciferase (siCtrl) or CENP-E (siCENP-E) for 48 h prior to fixation. Nocodazole was administered for 20 h before analysis.
    Mouse Anti Zw10, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zw10/ZW10+Antibody/pm39245571-45-32-34
    Average 93 stars, based on 1 article reviews
    mouse anti zw10 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti zw10  (Danaher Inc)
    86
    Danaher Inc anti zw10
    K250-BubR1 acetylation is involved in the maintenance of crescent-shaped fibrous corona. ( A ) Representative images of immunostaining with anti-MAD2 <t>and</t> <t>anti-ZW10</t> antibodies after induction of BubR1-WT, -K250R , and -K250Q expression in HeLa-FRT-TO cells. Nocodazole (200 ng/ml) alone or with MG132 was applied before fixation. Endogenous BubR1 was depleted via siRNA. Scale bar, 5 μm. ( B ) Representative SIM images of immunostained ZW10 at kinetochores of HeLa cells expressing FLAG-tagged BubR1-WT, -K250R , or -K250Q following double thymidine block and release. FRT/TO HeLa cells were treated with doxycycline for 55 h to induce expression of ectopic BubR1 variants. Endogenous BubR1 was depleted using siRNA targeting the 3′ UTR. Cells were fixed for immunostaining 10 h after the final thymidine release to enrich the mitotic population. ( C ) Effects of BubR1 acetylation status on CENP-E and RZZ complex formation. Cells were treated with nocodazole alone (+Noc) or with MG132 (+Noc + MG132). Relative protein levels were measured using a densitometer, and the ratios are indicated at the bottom. ( D ) Representative images showing immunostained ZW10 and anti-CENP-A antibodies in FRT/TO HeLa cells expressing BubR1-WT, K250R , or K250Q with (siCtrl) or without CENP-E (siCENP-E). Cells were transfected with siRNA targeting luciferase (siCtrl) or CENP-E (siCENP-E) for 48 h prior to fixation. Nocodazole was administered for 20 h before analysis.
    Anti Zw10, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zw10/pm39018254-316-71-72
    Average 86 stars, based on 1 article reviews
    anti zw10 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    K250-BubR1 acetylation is involved in the maintenance of crescent-shaped fibrous corona. ( A ) Representative images of immunostaining with anti-MAD2 and anti-ZW10 antibodies after induction of BubR1-WT, -K250R , and -K250Q expression in HeLa-FRT-TO cells. Nocodazole (200 ng/ml) alone or with MG132 was applied before fixation. Endogenous BubR1 was depleted via siRNA. Scale bar, 5 μm. ( B ) Representative SIM images of immunostained ZW10 at kinetochores of HeLa cells expressing FLAG-tagged BubR1-WT, -K250R , or -K250Q following double thymidine block and release. FRT/TO HeLa cells were treated with doxycycline for 55 h to induce expression of ectopic BubR1 variants. Endogenous BubR1 was depleted using siRNA targeting the 3′ UTR. Cells were fixed for immunostaining 10 h after the final thymidine release to enrich the mitotic population. ( C ) Effects of BubR1 acetylation status on CENP-E and RZZ complex formation. Cells were treated with nocodazole alone (+Noc) or with MG132 (+Noc + MG132). Relative protein levels were measured using a densitometer, and the ratios are indicated at the bottom. ( D ) Representative images showing immunostained ZW10 and anti-CENP-A antibodies in FRT/TO HeLa cells expressing BubR1-WT, K250R , or K250Q with (siCtrl) or without CENP-E (siCENP-E). Cells were transfected with siRNA targeting luciferase (siCtrl) or CENP-E (siCENP-E) for 48 h prior to fixation. Nocodazole was administered for 20 h before analysis.

    Journal: Nucleic Acids Research

    Article Title: Linking kinetochore attachment to checkpoint control: the role of Aurora B in BubR1 acetylation

    doi: 10.1093/nar/gkaf1517

    Figure Lengend Snippet: K250-BubR1 acetylation is involved in the maintenance of crescent-shaped fibrous corona. ( A ) Representative images of immunostaining with anti-MAD2 and anti-ZW10 antibodies after induction of BubR1-WT, -K250R , and -K250Q expression in HeLa-FRT-TO cells. Nocodazole (200 ng/ml) alone or with MG132 was applied before fixation. Endogenous BubR1 was depleted via siRNA. Scale bar, 5 μm. ( B ) Representative SIM images of immunostained ZW10 at kinetochores of HeLa cells expressing FLAG-tagged BubR1-WT, -K250R , or -K250Q following double thymidine block and release. FRT/TO HeLa cells were treated with doxycycline for 55 h to induce expression of ectopic BubR1 variants. Endogenous BubR1 was depleted using siRNA targeting the 3′ UTR. Cells were fixed for immunostaining 10 h after the final thymidine release to enrich the mitotic population. ( C ) Effects of BubR1 acetylation status on CENP-E and RZZ complex formation. Cells were treated with nocodazole alone (+Noc) or with MG132 (+Noc + MG132). Relative protein levels were measured using a densitometer, and the ratios are indicated at the bottom. ( D ) Representative images showing immunostained ZW10 and anti-CENP-A antibodies in FRT/TO HeLa cells expressing BubR1-WT, K250R , or K250Q with (siCtrl) or without CENP-E (siCENP-E). Cells were transfected with siRNA targeting luciferase (siCtrl) or CENP-E (siCENP-E) for 48 h prior to fixation. Nocodazole was administered for 20 h before analysis.

    Article Snippet: Commercially sourced antibodies used in this study include anti-BubR1 (612 503; BD Biosciences), anti-α-tubulin-FITC (F2168; Upstate), anti-Centromere protein antibody (15–235; Antibodies Inc.), anti-HDAC2 (ab12169; Abcam), anti-HDAC3 (ab7030; Abcam), anti-CDC20 (A15656; ABclonal), anti-MAD2 (A11469; ABclonal), anti-Cyclin B (sc-245; Santa Cruz Biotechnology), anti-β-actin (A700-057; Bethyl), anti-CDC27 (BD 610455; BD Biosciences), anti-FLAG (F1804; Sigma–Aldrich), anti-GAPDH (#2118; Cell Signaling Technology), anti-CENP-A (ab13939;Abcam), anti-ZW10 (sc-81430; Santa Cruz Biotechnology), anti-Myc (sc-40; Santa Cruz Biotechnology), anti-AIM-1 (BD611082; BD Biosciences), anti-Vinculin (sc-73614; Santa Cruz Biotechnology), anti-AurB-pT232 (636 102; BioLegend), anti-PLK1 (ab17057; Abcam), anti-mCherry (ab125096; Abcam), anti-Bub3 (611 730; BD Biosciences), ani-CENP-E (A15263; ABclonal), Cyclin B (sc-245; Santa Cruz Biotechnology), anti-pH3 (06–570; EMD Millipore), anti-pan-Phospho-serine (AP0932; ABclonal), and anti-Cdc25C (A12234, ABclonal).

    Techniques: Immunostaining, Expressing, Blocking Assay, Transfection, Luciferase

    AurkB-AcK250–BubR1 pathway coordinates the unattachment signal to the maintenance of fibrous corona and SAC. (A, B) Effects of AurkB-mediated phosphorylation and subsequent K250 acetylation in fibrous corona expansion. ( A ) SIM images of anti-Bub1 or anti-MAD2 immunostaining in nocodazole-treated cells are shown. The indicated BubR1 constructs were transfected with siBubR1 targeting the 3′ UTR 48 h before fixation, and nocodazole (200 ng/ml) was applied for 20 h. Volumes were measured from the immunofluorescence assays shown. Number of cells scored: Bub1 in WT, n = 63; Bub1 in S16A, n = 64; Bub1 in S39A, n = 70; MAD2 in WT, n = 196; MAD2 in S16A, n = 196; MAD2 in S39A, n = 69 (mean ± s.e.m.). ( B ) SIM images of anti-ZW10 immunostaining in nocodazole-treated cells. Endogenous BubR1 was depleted via co-transfection with siBubR1. Nocodazole (200 ng/ml) was administered for 20 h, two days post transfection. Insets show enlarged images of ZW10 and CREST staining. Scale bar, 5 μm. ( C ) Volume of ZW10 measured from the immunofluorescence assay shown in panel (B). Number of cells scored: WT, n = 27; S16A, n = 29; S39A, n = 27; S16A;K250Q, n = 31; S39A;K250Q, n = 32; K250Q, n = 29; S16D, n = 31; S39D, n = 32; S16D;K250R, n = 27; S39D;K250R, n = 27; K250R, n = 27 (mean ± s.e.m.). ( D ) Model illustrating the coordination of AurkB-mediated phosphorylation and K250 acetylation in spindle checkpoint signaling. At unattached kinetochores, AurkB phosphorylates BubR1 at S39 (and S16 as well), promoting BubR1 acetylation at K250 by PCAF. This acetylation ensures the maintenance of the RZZ complex and MCC. It also sustains CENP-E at the kinetochore, preparing lateral to end-on attachment (left). Upon successful end-on capture, PP2A activity recruited by AcK250–BubR1 antagonizes AurkB activity, stabilizing KT-MT attachment. Simultaneously, BubR1 immediately deacetylates and degrades through APC/C-mediated ubiquitination, resulting in MCC disassembly and SAC silencing.

    Journal: Nucleic Acids Research

    Article Title: Linking kinetochore attachment to checkpoint control: the role of Aurora B in BubR1 acetylation

    doi: 10.1093/nar/gkaf1517

    Figure Lengend Snippet: AurkB-AcK250–BubR1 pathway coordinates the unattachment signal to the maintenance of fibrous corona and SAC. (A, B) Effects of AurkB-mediated phosphorylation and subsequent K250 acetylation in fibrous corona expansion. ( A ) SIM images of anti-Bub1 or anti-MAD2 immunostaining in nocodazole-treated cells are shown. The indicated BubR1 constructs were transfected with siBubR1 targeting the 3′ UTR 48 h before fixation, and nocodazole (200 ng/ml) was applied for 20 h. Volumes were measured from the immunofluorescence assays shown. Number of cells scored: Bub1 in WT, n = 63; Bub1 in S16A, n = 64; Bub1 in S39A, n = 70; MAD2 in WT, n = 196; MAD2 in S16A, n = 196; MAD2 in S39A, n = 69 (mean ± s.e.m.). ( B ) SIM images of anti-ZW10 immunostaining in nocodazole-treated cells. Endogenous BubR1 was depleted via co-transfection with siBubR1. Nocodazole (200 ng/ml) was administered for 20 h, two days post transfection. Insets show enlarged images of ZW10 and CREST staining. Scale bar, 5 μm. ( C ) Volume of ZW10 measured from the immunofluorescence assay shown in panel (B). Number of cells scored: WT, n = 27; S16A, n = 29; S39A, n = 27; S16A;K250Q, n = 31; S39A;K250Q, n = 32; K250Q, n = 29; S16D, n = 31; S39D, n = 32; S16D;K250R, n = 27; S39D;K250R, n = 27; K250R, n = 27 (mean ± s.e.m.). ( D ) Model illustrating the coordination of AurkB-mediated phosphorylation and K250 acetylation in spindle checkpoint signaling. At unattached kinetochores, AurkB phosphorylates BubR1 at S39 (and S16 as well), promoting BubR1 acetylation at K250 by PCAF. This acetylation ensures the maintenance of the RZZ complex and MCC. It also sustains CENP-E at the kinetochore, preparing lateral to end-on attachment (left). Upon successful end-on capture, PP2A activity recruited by AcK250–BubR1 antagonizes AurkB activity, stabilizing KT-MT attachment. Simultaneously, BubR1 immediately deacetylates and degrades through APC/C-mediated ubiquitination, resulting in MCC disassembly and SAC silencing.

    Article Snippet: Commercially sourced antibodies used in this study include anti-BubR1 (612 503; BD Biosciences), anti-α-tubulin-FITC (F2168; Upstate), anti-Centromere protein antibody (15–235; Antibodies Inc.), anti-HDAC2 (ab12169; Abcam), anti-HDAC3 (ab7030; Abcam), anti-CDC20 (A15656; ABclonal), anti-MAD2 (A11469; ABclonal), anti-Cyclin B (sc-245; Santa Cruz Biotechnology), anti-β-actin (A700-057; Bethyl), anti-CDC27 (BD 610455; BD Biosciences), anti-FLAG (F1804; Sigma–Aldrich), anti-GAPDH (#2118; Cell Signaling Technology), anti-CENP-A (ab13939;Abcam), anti-ZW10 (sc-81430; Santa Cruz Biotechnology), anti-Myc (sc-40; Santa Cruz Biotechnology), anti-AIM-1 (BD611082; BD Biosciences), anti-Vinculin (sc-73614; Santa Cruz Biotechnology), anti-AurB-pT232 (636 102; BioLegend), anti-PLK1 (ab17057; Abcam), anti-mCherry (ab125096; Abcam), anti-Bub3 (611 730; BD Biosciences), ani-CENP-E (A15263; ABclonal), Cyclin B (sc-245; Santa Cruz Biotechnology), anti-pH3 (06–570; EMD Millipore), anti-pan-Phospho-serine (AP0932; ABclonal), and anti-Cdc25C (A12234, ABclonal).

    Techniques: Phospho-proteomics, Immunostaining, Construct, Transfection, Immunofluorescence, Cotransfection, Staining, Activity Assay, Ubiquitin Proteomics